CMR Surgical vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 52)
CMR Surgical logo

CMR Surgical

ChallengerHealthcare

Surgical Robotics

CMR Surgical makes the Versius robotic surgery system used in 30+ countries across 30,000+ procedures; raised $1.43B total; received FDA clearance in Oct 2024; raised $200M in Apr 2025; exploring ~$4B sale.

AI VisibilityBeta
Overall Score
C52
Category Rank
#286 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
53
Gemini
52

About

CMR Surgical is a Cambridge, UK-based medical robotics company that developed Versius, a modular, portable robotic surgery system designed to integrate into any standard operating room without requiring dedicated infrastructure. Founded in 2014, CMR Surgical built Versius to be smaller, lighter, and more flexible than established competitors, enabling surgeons to perform minimally invasive laparoscopic procedures — including cholecystectomy, hernia repair, and colorectal surgery — with robotic precision. Versius uses a wristed instrument design that mimics natural hand and wrist movements, providing surgeons enhanced dexterity within confined surgical spaces.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

52
Overall Score
93
#286
Category Rank
#1
83
AI Consensus
80
stable
Trend
stable
50
ChatGPT
94
53
Perplexity
89
52
Gemini
94
55
Claude
92
57
Grok
98

Key Details

Category
Surgical Robotics
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.